Den Mark Pharmaceuticals : Manufacturer and Distributor of Finished Dosages with Immense Industry Experience

By: Samad Hussain Patanwala, Founder & Managing Director, Den Mark Pharmaceuticals

Photo:img

The Indian Pharmaceutical sector is one of the most emerging globally and is one of the largest generics exporters in the world. Various factors are at play simultaneously that are driving the growth in this segment. Native manufacturing of APIs has hugely boosted the production of finished dosage formulations in the country and also helped drive exports. Technology innovations and emergence of sustainable packaging practices have helped in product efficacy and shelf lives. Government initiatives like “Make in India” have further boosted the motivation of manufacturers to go global with their products.

However, several challenges prevail in this sector for both manufacturers and consumers at large. Growth in the manufacturing of counterfeit drugs has been skyrocketing and in an emerging market like India where the certification process is not regulated enough, many such cases have emerged over the past few years.

To combat this problem, Den Mark Pharmaceuticals has created a definitive distribution process for the sale of its products manufactured at its WHO GMP-Certified Pharma manufacturing facility. Starting out as a humble medicine shop in 1990, then expanding to distribution, and finally backward integrating to become a manufacturer, the company has gathered an accurate understanding of the market dynamics.

The company currently manufactures and distributes many finished dosage formulations in the form of tablets, capsules, liquids, and ointments. The company’s manufacturing facility is based in Roorkee, Uttarakhand and it operates from Mumbai. The manufacturing facility of Den Mark Pharmaceuticals is WHO GMP certified. “Our products are also approved in Kenya, Philippines, and Yemen and we are currently exporting to these countries and also having a distribution network pan India. We always manufacture high-grade formulations and market both our generic and branded products all across the country. As a distributor of pharmaceuticals, we are currently supplying to 8000+ medical stores and procuring products from 150+ manufacturers”, mentioned Samad Hussain Patanwala, Founder & Managing Director, Den Mark Pharmaceuticals.

The company is utterly watchful about the wastage produced from its manufacturing facility and has established an Effluent Treatment Plant (ETP), 1500 meters away from the manufacturing unit

Industry Expertise Apart from manufacturing its own set of formulations, the company is also working as a pharmaceutical contract manufacturer for some of the reputed organizations including Alkem, Wings Pharma and others. Only through the delivery of quality products to its clients and consumers, the company has been able to make a mark in the market. When it comes to quality control, it leaves no stone unturned in proper checking and supervision of all the finished products ready to hit the market. It has a testing lab which is approved by the government and spans 9000 square feet. 40+ certified professionals are employed in that facility to make the quality checks for all the manufactured products. Because it is also a contract manufacturer with various MNCs working in India, they work in collaboration to keep the quality in place. Executives from these organizations visit Den Mark Pharmaceuticals’ manufacturing facility at timely intervals and conduct quality audits of the machinery and products. “This modern infrastructure empowers us to generate highly accurate and reliable data for dossier submission. By adhering to the highest quality standards, we ensure that our pharmaceutical products meet the regulatory requirements essential for market approval and compliance”, stated Samad Patanwala.

Sustainability Initiatives We can see globally that organizations are taking various initiatives to promote environmental sustainability and Den Mark Pharmaceuticals is no exception. The company is utterly watchful about the wastage produced from its manufacturing facility and has established an Effluent Treatment Plant (ETP), 1500 meters away from the manufacturing unit. All the wastage produced directly travels to the ETP and is treated to extract water for irrigation. The substances that are harmful to the environment are timely collected by government officials under strict supervision so that there is no chance of contamination. It is the largest ETP that any manufacturing plant in Roorkee has until now. “All the water that is produced in our ETP is used for irrigation of the plantations that we have done in the manufacturing premises. We aim to plant more trees to lessen the amount of pollution created in the environment. We also have processes in place for usage of less amount of diesel in our facility to promote environmental sustainability”, said Samad.

Future Endeavors Den Mark Pharmaceuticals has gained significant trust and recognition in the market because of its qualitycentricity and established distribution network. Looking ahead, it plans on opening six different manufacturing facilities dedicated to specific medications by 2026. All the departments combined, the manufacturing area that is up for construction is 110 thousand square feet. “We are also in the process of getting EU GMP approved by the end of 2026”, concluded Samad.

Samad Hussain Patanwala, Founder & Managing Director, Den Mark Pharmaceuticals Samad Hussain Patanwala, the dynamic leader and owner of Den Mark Pharamceuticals, is a visionary entrepreneur known for his exceptional leadership and innovative approach. With a keen understanding of the pharmaceutical industry, he has steered the company towards success through strategic planning and a commitment to excellence. His forward-thinking mindset has played a pivotal role in adapting to industry changes, embracing technology, and fostering a culture of continuous improvement. His hands-on approach and passion for innovation inspire the team to reach new heights in the pharmaceutical sector.